Download presentation
Presentation is loading. Please wait.
Published byDevi Budiman Modified over 6 years ago
1
The Evolving Treatment Landscape in Atopic Dermatitis
2
Introduction
3
Pathomechanisms of AD
4
IL-4 and IL-13 Further Impair Barrier Function: A Vicious Cycle
5
New Therapeutic Targets for AD
6
Evolution of Treatment Landscape in AD
7
Key Challenges in Managing Patients With AD
8
Evolution of Treatment Landscape in AD (cont)
9
Current Therapy Recommendations for Patients With AD
10
Current Therapy Recommendations for Patients With AD (cont)
11
Real-World Use of Immunosuppressant Therapies for AD
12
Use of Systemic Therapies in Patients With AD
13
Dupilumab AD Clinical Development Phase 3 Program
14
SOLO-1 and SOLO-2: Primary and Secondary Endpoints
15
SOLO-1 and SOLO-2: Pruritus
16
SOLO-1 and SOLO-2: Primary and Secondary Endpoints (cont)
17
CHRONOS: Efficacy Over 52 Weeks
18
CHRONOS: Sustained Improvements in IGA 0/1 Through 52 Weeks
19
CAFÉ: Primary Endpoint
20
CAFÉ: Secondary Endpoints at Week 16
21
Effect of Dupilumab on Quality of Life
22
Dupilumab: Safety
23
Agents Under Investigation
24
Conclusions
25
Abbreviations
26
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.